News Search Results
May 28, 2025, 09:00 ET Mitsubishi Tanabe Pharma America Announces U.S. FDA Acceptance of New Drug Application Resubmission for Investigational ND0612 for the Treatment of Motor Fluctuations in Parkinson's Disease
combination therapies and technologies. NeuroDerm is an integrated pharmaceutical and medical technology company developing central nervous system (CNS) product candidates. For additional information, please visit NeuroDerm's website at
More news about: Mitsubishi Tanabe Pharma America
May 28, 2025, 08:08 ET NCCN Recognizes Outstanding Contributions in Oncology with 2025 Awards
at University of Alabama at Birmingham (UAB)—Chair of the NCCN Guidelines Panel for Central Nervous System Cancers (CNS) since 2017 and Member since 2013—also received a 2025 Excellence in Engagement Award. Dr. Nabors was also honored for his commitment to NCCN's
More news about: National Comprehensive Cancer Network
May 27, 2025, 08:30 ET Cipla North America Partners with American Lung Association for 2025 LUNG FORCE Walk to Champion Respiratory Health
North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms
More news about: Cipla
May 27, 2025, 08:30 ET STORM Therapeutics Announces First Patient Dosed in Clinical Collaboration to Evaluate STC-15 in Combination with LOQTORZI® and Appointment of Atif Abbas, M.D., as Chief Medical Officer
discovery of breakthrough small molecule drugs that precisely reprogram cells through RNA biology for the treatment of cancer, inflammation, viruses and CNS diseases. STORM's lead product, STC-15, is the first RNA modifying enzyme inhibitor to enter human clinical development. STC-15 is currently being
More news about: STORM Therapeutics
May 27, 2025, 02:00 ET MEXC Ventures at the Forefront of Korea's Blockchain-AI University Innovation Showcase
university-driven ideathon. MEXC Ventures served as a premier sponsor of the blockchain track, alongside the Korea Internet & Security Agency (KISA), LG CNS, and Tether. The AI track, organized under the same program, was supported by Koscom and Toss, contributing to a diverse and collaborative innovation
More news about: MEXC Ventures
May 27, 2025, 02:00 ET MEXC Ventures at the Forefront of Korea's Blockchain-AI University Innovation Showcase
university-driven ideathon. MEXC Ventures served as a premier sponsor of the blockchain track, alongside the Korea Internet & Security Agency (KISA), LG CNS, and Tether. The AI track, organized under the same program, was supported by Koscom and Toss, contributing to a diverse and collaborative
More news about: MEXC Ventures
May 26, 2025, 17:31 ET Rett Syndrome Market Sees Momentum with Novel Gene and Protein-Targeted Therapies | DelveInsight
introducing a functional MECP2 gene into cells of the central nervous system (CNS). The therapy features an innovative miRNA-Responsive Auto-Regulatory Element (miRARE) technology, which helps regulate MECP2 expression in individual CNS cells, minimizing the risk of overexpression. TSHA-102 has been
More news about: DelveInsight Business Research, LLP
May 26, 2025, 06:06 ET Dizal to Highlight its Portfolio Advances in Hematologic Malignancies and Lung Cancer at ASCO 2025
both GCB and non-GCG subtypes, an important feature. With full BBB penetration and a favorable safety profile, it also shows promise in patients with CNS involvement, who typically confront a poor prognosis." DZD6008: A 4th generation
More news about: Dizal Pharmaceutical
May 25, 2025, 21:00 ET World's First -- XellSmart's Allogeneic iPSC-derived Regenerative Cell Therapy for Spinal Cord Injury Officially Approved by the U.S. FDA for a Registrational Phase I Clinical Trial
XellSmart has been dedicated to the development of clinical-grade, allogeneic, off-the-shelf iPSC-derived cell therapies for central nervous system (CNS) diseases that currently lack effective treatment options. Up until now, XellSmart has secured formal approvals from both China's
More news about: XellSmart
May 22, 2025, 21:00 ET Rayakan Prestasi Industri Properti, American Standard dan GROHE dari LIXIL Dukung Asia Pacific International Property & Hotel Awards 2025-2026
Tenggara berhasil meraih penghargaan utama dari LIXIL. Salah satu karya tanah air, yaitu Stone Experience Center karya MM Galleri bersama CNS Designworks dari Indonesia meraih GROHE Luxury Award. Penghargaan ini menyoroti konsep New Luxury,
More news about: Lixil
May 22, 2025, 18:02 ET Cohen & Steers Closed-End Opportunity Fund, Inc. (FOF) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS) About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income,
More news about: Cohen & Steers, Inc.
May 22, 2025, 17:47 ET Cohen & Steers Total Return Realty Fund, Inc. (RFI) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.com/Symbol: (NYSE: CNS) About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income,
More news about: Cohen & Steers, Inc.
May 22, 2025, 17:45 ET Cohen & Steers REIT and Preferred and Income Fund, Inc. (RNP) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.com/Symbol: (NYSE: CNS) About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income,
More news about: Cohen & Steers, Inc.
May 22, 2025, 17:43 ET Cohen & Steers Quality Income Realty Fund, Inc. (RQI) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS) About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income,
More news about: Cohen & Steers, Inc.
May 22, 2025, 17:29 ET Cohen & Steers Infrastructure Fund, Inc. (UTF) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS) About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income,
More news about: Cohen & Steers, Inc.
May 22, 2025, 17:05 ET Lilly announces details of presentations at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
updated results from a Phase 1/2 study of olomorasib, a potent and highly selective second-generation inhibitor of KRAS G12C with preliminary evidence of CNS activity, in combination with pembrolizumab in patients with KRAS G12C-mutant advanced non-small cell lung cancer (NSCLC) and in combination with
More news about: Eli Lilly and Company
May 22, 2025, 08:00 ET Corundum Neuroscience and Corundum Systems Biology to Host Panel Sessions at First Ever SXSW London
May 22, 2025 /PRNewswire/ -- Corundum Neuroscience (CNS), the neuroscience venture builder and fund, and Corundum Systems Biology (CSB),
More news about: Corundum Neuroscience; Corundum Systems Biology
May 22, 2025, 00:00 ET LG CNS showcases AI-Enhanced 'PerfecTwin ERP Edition' in the U.S. at SAP Sapphire 2025
in ERP and continue to support innovation for global clients," said Hanshin Nae, Senior Vice President of LG CNS Enterprise Solutions Division. About LG CNS LG CNS is a leading Korean AX (AI Transformation) company that continues to pioneer various emerging technologies, including
More news about: LG CNS
May 21, 2025, 11:00 ET Astellas and MBC BioLabs Announce the 2025 Astellas Future Innovator Prize Awarded to DeepSeq.AI & Serna Bio
Business Development at Astellas. "We congratulate DeepSeq.AI and Serna Bio on their exceptional work in oncology and infectious diseases, as well as CNS, respectively. Through this award, and in collaboration with MBC BioLabs, we are proud to support their efforts to advance cutting-edge science into
More news about: Astellas Pharma Inc.
May 21, 2025, 07:30 ET NLS Pharmaceutics to Present New Data on the Dual Efficacy of Mazindol ER in Fentanyl Reward and Withdrawal at the 2025 ASCP Annual Meeting
to present and discuss the latest advances in CNS therapeutics. About NLS Pharmaceutics Ltd. NLS Pharmaceutics Ltd. is a Swiss-based clinical-stage biopharmaceutical company developing innovative therapies for rare and complex CNS disorders. The company's pipeline includes drug
More news about: NLS Pharmaceutics Ltd.
May 20, 2025, 11:58 ET Alacrita Expands Investor Support Services with Appointment of Lucas Rodriguez, PhD
on novel pain therapies. Previously, as an Alacrita consultant, he provided strategic insight across multiple therapeutic areas including oncology, CNS, pain, metabolic disorders, liver disease, and cardiovascular disease. His appointment supports Alacrita's expanded
More news about: Alacrita
May 20, 2025, 09:00 ET INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANA
oncology, diabetes, central nervous system ("CNS") disorders, and B-cell-mediated autoimmune diseases. The Company's product candidates include, among others, SC291 for the treatment of, inter alia, B-cell malignancies; SC379 for the treatment of certain CNS disorders; and SG299, which is part of
More news about: Pomerantz LLP
May 20, 2025, 08:08 ET Eisai Demonstrates Commitment to Oncology Innovation at ASCO 2025
3-5 hemorrhage occurred in 2% of LENVIMA-treated patients, including 1 fatal intracranial hemorrhage among 16 patients who received LENVIMA and had CNS metastases at baseline. In RCC, grade 3-5 hemorrhage occurred in 8% of LENVIMA + everolimus–treated patients, including 1 fatal cerebral hemorrhage.
More news about: Eisai Inc.
May 19, 2025, 15:01 ET 알라마르 바이오사이언스, 획기적인 혈액 기반 뇌 유래 pTau 분석법으로 NULISAseq™ 중추신경계 질환 패널 120 확장
검출할 수 있는 능력이 매우 중요하다고 강조한다. 알라마르의 새로운 CNS 패널은 이러한 생체표지자의 진단 정확도와 임상 활용성을 더욱 개선할 수 있는 전례 없는 기회를 제공하며, 이는 환자 치료 및 임상 연구에 극적인 영향을 미칠 것"이라고 말했다. 알라마르 바이오사이언스는 조기 진단, 환자 분류, 치료 모니터링을 주도하는 생체표지자 인사이트를 확보하기 위해 신경과학 커뮤니티와의 협력을 지속적으로 이어 나갈 계획이다. NULISAseq CNS Disease Panel 120 및 알라마르 바이오사이언스의 단백질체학
More news about: Alamar Biosciences, Inc.
May 19, 2025, 08:17 ET SK Life Science Launches Its Second National Ad, Continuing to Lead with the Only Direct-to-Consumer Commercial for an Anti-Seizure Drug in the U.S.
SK Life Science, Inc., a global leader in developing treatments for central nervous system (CNS) disorders and a subsidiary of SK Biopharmaceuticals Co., Ltd., today announced the launch of a new nationwide direct-to-consumer (DTC)
More news about: SK Life Science, Inc.